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Purpose: To investigate whether assessment of bone strength with 
quantitative computed tomography (CT) in combination with 
dual-energy x-ray absorptiometry (DXA) is cost-effective as 
a screening tool for osteoporosis in postmenopausal women.
Materials and 
Methods:
A state-transition microsimulation model of osteoporosis for 
postmenopausal women aged 55 years or older was devel-
oped with a lifetime horizon and U.S. societal perspective. 
All model inputs were derived from published literature. 
Three strategies were compared: no screening, DXA with T 
score–dependent rescreening intervals, and a combination 
of DXA and quantitative CT with different intervals (3, 5, 
and 10 years) at different screening initiation ages (55–65 
years). Oral bisphosphonate therapy was started if DXA hip 
T scores were less than or equal to 22.5, 10-year risk for 
hip fracture was greater than 3% (World Health Organiza-
tion Fracture Risk Assessment Tool score, or FRAX), 10-
year risk for major osteoporotic fracture was greater than 
20% (FRAX), quantitative CT femur bone strength was less 
than 3000 N, or occurrence of first fracture (eg, hip, ver-
tebral body, wrist). Outcome measures were incremental 
cost-effectiveness ratios (ICERs) in 2015 U.S. dollars per 
quality-adjusted life year (QALY) gained and number of 
fragility fractures. Probabilistic sensitivity analysis was also 
performed.
Results: The most cost-effective strategy was combined DXA and 
quantitative CT screening starting at age 55 with quantitative 
CT screening every 5 years (ICER, $2000 per QALY). With 
this strategy, 12.8% of postmenopausal women sustained hip 
fractures in their remaining life (no screening, 18.7%; DXA 
screening, 15.8%). The corresponding percentages of verte-
bral fractures for DXA and quantitative CT with a 5-year in-
terval, was 7.5%; no screening, 11.1%; DXA screening, 9%; 
for wrist fractures, 14%, 17.8%, and 16.4%, respectively; for 
other fractures, 22.6%, 30.8%, and 27.3%, respectively. In 
probabilistic sensitivity analysis, DXA and quantitative CT at 
age 55 years with quantitative CT screening every 5 years was 
the best strategy in more than 90% of all 1000 simulations (for 
thresholds of $50 000 per QALY and $100 000 per QALY).
Conclusion: Combined assessment of bone strength and bone mineral 
density is a cost-effective strategy for osteoporosis screen-
ing in postmenopausal women and has the potential to pre-
vent a substantial number of fragility fractures.
q RSNA, 2017
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with healthy women, without differ-
ences in T scores (9). Therefore, bone 
strength testing provides information 
not captured at DXA. Because execut-
ing a prospective fracture prediction 
study is expensive and requires exten-
sive resources, it would be useful to 
know whether bone strength testing 
has the potential to be cost-effective, 
considering the higher costs of CT-
based bone strength testing compared 
with those of DXA. We hypothesized 
that bone strength testing would be 
cost-effective as a screening tool. The 
purpose of our study was to inves-
tigate whether assessment of bone 
strength with quantitative CT in com-
bination with DXA is cost-effective as 
a screening tool for osteoporosis in 
postmenopausal women.
Materials and Methods
We conducted a cost-utility analysis to 
compare different screening strategies 
for osteoporosis by using a societal per-
spective with direct and indirect costs 
and a lifetime horizon.
Model Structure
We developed a state transition micro-
simulation model of osteoporosis by 
The major limitation of DXA is 
that its use for detection of increased 
fracture risk is poor in the majority 
of individuals (5). Most patients with 
fragility fractures do not meet the 
DXA criterion for osteoporosis (ie, T 
score . 22.5) (6,7). DXA is a low-
resolution two-dimensional technique 
that does not completely capture im-
paired bone strength in patients with 
osteoporosis. Modalities that allow as-
sessment of bone strength are quan-
titative computed tomography (CT) 
and magnetic resonance (MR) imag-
ing (8,9). A bone strength estimate 
is computed from bone images with a 
method called finite element analysis 
(10). The three-dimensional images of 
a patient’s bone are transformed into a 
three-dimensional model consisting of 
multiple voxels. Each voxel is assigned 
a material property (cortex, trabecu-
lae) on the basis of imaging charac-
teristics in that voxel. This results in a 
three-dimensional model of the bone 
that simulates the material strength of 
the trabeculae and cortex. Virtual me-
chanical testing of this three-dimen-
sional model simulates and quantifies 
the force (bone strength) needed to 
fracture the model (10). There are 
only a few published studies in which 
the ability of bone strength assess-
ment and DXA to predict incidents 
of osteoporotic fracture are exam-
ined. Bone strength testing improves 
vertebral fracture risk assessment 
in elderly men when compared with 
DXA (11). Low bone strength also 
is associated with an increased risk 
of hip and vertebral fractures, simi-
lar to the DXA-based thresholds for 
BMD for osteoporosis (12). Postmen-
opausal women with hip fractures 
show lower bone strength compared 
https://doi.org/10.1148/radiol.2017161259
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Advances in Knowledge
 n Bone strength testing with quan-
titative CT in addition to dual-
energy x-ray absorptiometry 
(DXA) for determination of bone 
mineral density could be a 
cost-effective strategy for osteo-
porosis screening in postmeno-
pausal women.
 n The lifetime risk for hip fracture 
of 55-year-old postmenopausal 
women in our model was sub-
stantially lower (12.8%) when a 
combined DXA and quantitative 
CT bone strength screening pro-
tocol was used compared with 
that when women did not un-
dergo screening (18.7%).
 n The most cost-effective strategy 
in our model was combined DXA 
and quantitative CT screening 
starting at age 55 years, with 
quantitative CT rescreening every 
5 years.
 n Increasing the costs of the quan-
titative CT bone strength test 
had little effect on the cost-effec-
tiveness results of bone strength 
screening.
Implication for Patient Care
 n The combined assessment of 
bone strength and bone mineral 
density in postmenopausal 
women has the potential to be a 
cost-effective strategy for osteo-
porosis screening and may pre-
vent a substantial number of fra-
gility fractures.
Osteoporosis is a major public health problem that results in high societal costs and physical 
impairment. The main clinical out-
come of osteoporosis is fracture due 
to low bone mass and deterioration 
in bone microarchitecture (1). In the 
United States, more than 2 million 
fractures each year are attributed to 
osteoporosis, and the direct annual 
costs are estimated at greater than 
$17 billion (2). The lifetime risk for 
hip fracture in a 50-year-old white 
woman is 16% (3), and the mortal-
ity rates in the first 3 months after 
hip fracture increase five- to eightfold 
(4). Given the aging population, the 
number of fractures and costs to so-
ciety are only expected to rise (2). 
Osteoporosis is operationally defined, 
in the absence of fragility fracture, 
as low bone mineral density (BMD) 
at dual-energy x-ray absorptiometry 
(DXA) (T score  22.5).
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transitioned to a postfracture state af-
ter an acute fracture, or died.
We derived transition probabilities 
between health states from published 
literature (Tables 1,2). All-causes mor-
tality of women in the general popula-
tion was derived from U.S. life tables 
(41). The risk of dying after a hip 
fracture was age dependent and in-
creased during the 1st year after the 
fracture (27). After the 1st year, the 
relative risk of dying decreased but 
remained higher than the background 
mortality (4). After a hip fracture, 20% 
of individuals required placement in 
nursing facilities for their remaining 
lifetime (35). We limited the maximum 
number of hip fractures for each indi-
vidual to two (once on each side). Only 
10-year risk for hip fracture and other 
major osteoporotic fracture for each 
individual on the basis of the number 
of assigned risk factors (factors, 0–6) 
and the BMD T score of the femoral 
neck (13).
The cohort transitioned through 
different health states in 3-month 
cycles for their remaining lifespan. 
The health states were no fracture, 
hip fracture, post–hip fracture, clini-
cal vertebral fracture, wrist fracture, 
other fracture (humerus, ribs, dis-
tal femur, tibia), post–all nonhip 
fractures, and death (Fig 1). In the 
first cycle, all individuals started 
in the no fracture state. In each cy-
cle they either stayed healthy (no 
fracture state), sustained a fracture, 
using modeling software (TreeAge Pro 
Health Care 2015; TreeAge Software, 
Williamstown, Mass). We simulated a 
hypothetical cohort of 1 million post-
menopausal women. We randomly as-
signed six risk factors (absent or pre-
sent) used in the paper chart version 
of the World Health Organization’s 
fracture risk assessment tool (FRAX) 
(13) to each individual on the basis 
of reported age-dependent prevalence 
(previous fracture [14], fractured hip 
in a parent [14,15]), current smoking 
[16], use of glucocorticoids [15], rheu-
matoid arthritis [17], and consump-
tion of three or more units of alcohol 
per day [15]). The model included a 
simulation of the U.S. Caucasian paper 
chart of the FRAX tool to calculate the 
Figure 1
Figure 1: State transition diagram. In the first cycle all individuals started in no fracture state. In each cycle they either stayed healthy  
(no fracture state), sustained an acute fracture, transitioned to postfracture state after acute fracture, or died (and therefore exited the model). 
Acute other fractures comprised those of the humerus, ribs, distal femur, and tibia.
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35% of all occurring vertebral compres-
sion fractures were considered clini-
cally apparent (34). Individuals could 
only sustain a maximum of one fracture 
type in each 3-month cycle.
Screening Strategies
We compared three types of screen-
ing strategies: no screening, DXA and 
FRAX, and combined DXA and quan-
titative CT (DXA/quantitative CT) and 
FRAX; each with screening initiation 
at ages 55, 60, and 65 years. FRAX 
risks were recalculated on the occasion 
of every DXA scan with all strategies. 
DXA rescreening intervals depended on 
the most current T score from the last 
DXA scan: every 15 years for women 
with normal BMD or mild osteopenia 
(T score . 21.5), every 5 years for 
those with moderate osteopenia (T 
score, 21.50 to 21.99), and every year 
for those with advanced osteopenia 
(T score, 2.00 to 22.49) (42). In the 
combined DXA/quantitative CT strat-
egies, all individuals were first screened 
with DXA and FRAX. We added bone 
strength testing (quantitative CT) at 
fixed intervals (3, 5, and 10 years) in 
individuals with T scores greater than 
22.5 who were not assigned for treat-
ment on the basis of the FRAX tool. 
We defined a femoral bone strength of 
less than 3000 N as low bone strength 
on the basis of the work of Keaveny 
et al (10). In all strategies, individuals 
assigned for treatment on the basis of 
DXA, FRAX tool, or quantitative CT or 
after any fracture were exempted from 
further screening, because they would 
be treated under current osteoporosis 
treatment guidelines. Overall, this re-
sulted in a total of 15 different screen-
ing strategies.
Bone Parameters
Table 2 provides the parameters we 
used to simulate bone quality. We as-
signed a BMD and a bone strength 
value to each individual at the start of 
the simulation, drawn from a normal 
distribution for that specific start age 
(36). During each cycle we simulated 
BMD and bone strength changes for 
each woman on the basis of her start 
value, current age, and whether the 
Table 1
Model Parameters
PSA
Variable* Base Case Data Distribution Data
Prevalence of clinical risk factors (%)
 Previous fracture (14)
  Age 55–64 years 7.6 Uniform (6.6, 8.7)
  Age 65–74 years 16.3 Uniform (14.3, 18.5)
  Age  75 years 29.4 Uniform (26.1, 32.9)
 Parent hip fracture (14,15) (%) 16 Uniform (14.5, 17.3)
 Current smoking (16) (%)
  Age 55–64 years 15.2 Uniform 6 3†
  Age  65 years 7.5 Uniform 6 3†
 Glucocorticoids (15) (%) 3 Uniform 6 1†
 Rheumatoid arthritis (17) (%) 0.98 Uniform (0.9, 1.07)
 Alcohol, three or more units per day (15) (%) 1 Uniform (0.5, 2)†
Direct costs ($)‡
 DXA (18) 41.68 Normal 6 5
 Quantitative CT plus $100 for bone strength  
analysis (18)
214.63 Normal 6 27
 Doctor visit (18) 73.3 Normal 6 9
 Alendronate (per y) (19) 76 Gamma 6 29
 Hip fracture (20) 25 758 Gamma 6 9659
 Clinical vertebral fracture (20) 10 535 Gamma 6 3951
 Wrist fracture (20) 5719 Gamma 6 2145
 Other fracture (20) 7014 Gamma 6 2630
 Nursing home (per y) (21) 80 300 Gamma 6 30 113
Indirect costs ($)§
 Age younger than 65 years
  Hip fracture (22–24) 7405 Uniform (3703–11108)
  Clinical vertebral fracture (22–24) 3149 Uniform (1575–4724)
  Wrist fracture (22–24) 2041 Uniform (1021–3062)
  Other fracture (22–24) 2682 Uniform (1341–4023)
 Age 65 years or older
  Hip fracture (22–24) 1219 Uniform (610–1829)
  Clinical vertebral fracture (22–24) 518 Uniform (259–777)
  Wrist fracture (22–24) 336 Uniform (168–504)
  Other fracture (22–24) 442 Uniform (221–663)
Relative risks
 Prior hip fracture (25) 1.56 Log-normal (1.23, 1.98)
 Prior nonhip fracture (25) 1.74 Log-normal (1.57, 1.92)
 Primary prevention
  Hip fracture (26) 0.79 Log-normal (0.44, 1.44)
  Vertebral fracture (osteoporosis) (26) 0.55 Log-normal (0.38, 0.80)
  Vertebral fracture (osteopenia) (26)|| 0.82 Log-normal (0.33, 2.07)
  Wrist fracture (26) 1.19 Log-normal (0.87, 1.62)
  Other fracture (26) 0.89 Log-normal (0.76, 1.04)
 Secondary prevention
  Hip fracture (26) 0.47 Log-normal (0.26, 0.85)
  Vertebral fracture (26) 0.55 Log-normal (0.43, 0.69)
  Wrist fracture (26) 0.5 Log-normal (0.34, 1.73)
  Other fracture (26) 0.77 Log-normal (0.64, 0.92)
 Death in 1st year after hip fracture (27)# 
  Age 57 years 14.5 Gamma ± 10
Table 1 (continues)
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strength, previous fracture, and pri-
mary or secondary prevention (Tables 
1, 2). We used reported fracture rates 
in women for each fracture site for age 
groups 55–59, 60–64, 65–69, 70–74, 
75–79, 80–84, and greater than or 
equal to 85 years (base risk of the gen-
eral population) (2,44). We multiplied 
that base risk by a T score factor de-
rived from relative risks below certain 
T score thresholds for hip fractures 
compared with that of the general pop-
ulation (Table 2) (36). These relative 
risks were further modified on the ba-
sis of bone strength by multiplying the 
relative risk by a bone strength factor 
(Table 2). The relative risk of fracture 
was increased if an individual had a 
prior hip or nonhip fracture on the ba-
sis of data from a meta-analysis (25). 
We applied relative risks for primary or 
secondary prevention of osteoporotic 
fractures for each fracture site, which 
were derived from a Cochrane data-
base systematic review (26).
Direct Costs
We used reported direct fracture costs 
for each fracture type (Table 1). These 
direct fracture costs accounted for 
surgery, hospital stay, and rehabilita-
tion. We projected all costs in 2015 
U.S. dollars, according to data from 
the U.S. Department of Labor and the 
U.S. Consumer Price Index for medical 
care for all urban consumers (45). We 
used 2015 Medicare reimbursement 
rates for DXA, quantitative CT, and 
physician office visits (18). For quanti-
tative CT costs, we used the costs for 
a CT scan of the hip. For postprocess-
ing of the images and bone strength 
analysis, we added $100. We assumed 
that there were physician office visits 
on the occasions of screening exami-
nations and once each quarter in the 
primary prevention scenario (if the 
patient was adherent to the treat-
ment) or after a first fracture. For sub-
jects receiving treatment, we applied 
the costs of the generic oral form of 
alendronate (19). For individuals in a 
nursing home, we applied the median 
2015 costs of nursing home care in the 
United States for a semiprivate room, 
on the basis of 365 days of care (21).
first fracture was sustained. Alendronate 
was given in 5-year cycles (ie, 5 years 
of treatment and a 5-year drug holiday) 
(43). Individuals’ BMD and bone strength 
slowly improved during treatment and 
slowly decreased during drug holidays 
(Table 2). We assumed an adherence to 
alendronate of 50% in the primary pre-
vention scenario and complete adherence 
after the first fracture.
Fracture Risk
In each cycle, we calculated the risk for 
each fracture site on the basis of these 
parameters: location, age, T score, bone 
individual was receiving therapy or not 
or was on a drug holiday. T scores for 
the model were calculated on the basis 
of each individual’s current BMD.
Treatment
The model included initiation of oral 
bisphosphonate (alendronate) treatment 
in these scenarios: (a) DXA with T score 
of less than or equal to 22.5; (b) 10-year 
risk for hip fracture of greater than 3% 
with the FRAX tool; (c) 10-year risk for 
major osteoporotic fracture of greater 
than 20% with the FRAX tool, low bone 
strength at quantitative CT or after the 
PSA
Variable* Base Case Data Distribution Data
Prevalence of clinical risk factors (%)
  Age 72 years 5.2 Gamma ± 10
  Age 80+ years 2.5 Gamma ± 10
 Death after 1st year after hip fracture (4) 1.78 Log-normal (1.33, 2.39)
Utilities#
 Base effectiveness in fracture-free health  
state (28)
  Age 55 years 0.837 Triangular ± 10
  Age 65 years 0.811 Triangular ± 10
  Age 75 years 0.771 Triangular ± 10
  Age 85 years 0.724 Triangular ± 10
 Utility modifier
  Hip fracture (29) 0.792 Triangular ± 10
  Clinical vertebral fracture (29) 0.626 Triangular ± 10
  Wrist fracture (29)** 0.977 Triangular ± 10
  Other fracture (29) 0.867 Triangular ± 10
  1st year after hip fracture (30) 0.797 Triangular ± 10
  Subsequent years after hip fracture (31) 0.9 Triangular ± 10
  After nonhip fracture (29,32)** 0.93 Triangular ± 10
  Nursing home placement (31) 0.4 Triangular ± 10
Others‡
 Clinical vertebral fractures (33) (%) 35 Beta 6 0.13
 Fracture modifier 1 Gamma 6 0.10
 Probability to end up in nursing home (34) (%) 20 Beta 6 0.08
 Adherence to alendronate (35) (%) 50 Beta 6 0.19
Note.—Unless otherwise indicated, data in parentheses are 95% confidence intervals. CTP code for doctor visit, 99213; DXA, 
77080; for quantitative CT, 77078; for bone strength analysis, 76377. PSA = probabilistic sensitivity analysis.
* Data in parentheses are reference numbers.
† Indicates an assumption.
‡ Base case data are means and PSA data are standard deviations.
§ Data in parentheses are the range.
|| No data for hip, others, wrist fracture for osteopenia.
# Base case data are means and PSA data are standard deviation percentage of the mean.
** Capped at maximum value of 1.
Table 1 (continued)
Model Parameters
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To calculate indirect costs, we used 
reported estimates on days unable to 
work for each fracture type (hip, 127 
days; vertebrae, 54 days; others, 46 
days; and wrist, 35 days) (22). We 
used annual averages (2013) of me-
dian weekly earnings for full-time and 
part-time working women in the United 
States, adjusted for that age group’s 
workforce participation (55–64 years 
and  65 years) (23,24). We applied 
indirect costs as onetime costs for each 
fracture event. We projected all indi-
rect costs in 2015 U.S. dollars.
Utilities
We used quality-adjusted life years 
(QALYs) to calculate the effectiveness 
of our strategies. We assigned an age-
dependent base effectiveness in the no 
fracture health state on the basis of 
representative U.S. values for health-
related quality-of-life scores (28). Each 
fracture state and postfracture state 
comprised a utility modifier with which 
the base value was multiplied in that cy-
cle (Table 1). Nursing home placement 
was associated with a substantial dis-
utility as reported in a systematic re-
view for utilities in osteoporosis-related 
health conditions (31).
Model Validation
We tested the external validity of our 
model by using a 65-year-old cohort of 
postmenopausal women who had not 
undergone screening. We compared 
the predicted fracture rates according 
to our model with reported fracture 
rates from independent studies not 
used for model inputs.
Main Analysis
We calculated incremental cost-ef-
fectiveness ratios (ICERs) for each 
strategy on the basis of the base case 
variables provided in Tables 1 and 2. 
We excluded strategies that were more 
costly but less effective than an alter-
native strategy (absolute dominance). 
We ruled out strategies if they were 
less costly than an alternative but had 
a higher ICER (weak dominance). We 
tracked all fracture events in the model 
and compared the number of fractures 
from the most cost-effective screening 
Table 2
Bone Mineral Density and Bone Strength Parameter
Variable* Base Case Data
PSA
Distribution Data
BMD
 Mean BMD at start (g/cm2) (36)†
  Age 25 years 0.86 Normal 6 0.12
  Age 55 years 0.71 Normal 6 0.12
  Age 65 years 0.682 Normal 6 0.114
  Age 75 years 0.618 Normal 6 0.099
 BMD loss per year without treatment (37) (%) 
  Age 50 years 0.109 Triangular 6 10
  Age 65 years 0.368 Triangular 6 10
  Age 70 years 0.471 Triangular 6 10
  Age 75 years 0.559 Triangular 6 10
  Age 80 years 0.647 Triangular 6 10
  Age 85 years 0.824 Triangular 6 10
 BMD increase per year with therapy (38) (%) 0.95 Gamma 6 0.356
 BMD loss per year during drug holiday (39) (%) 0.34 Gamma 6 0.127
 Relative risk for fracture based on hip T score  
(36) (T score factor)‡
  At age 65 years
   23.5 3.385 Triangular 6 10
   23 2.308 Triangular 6 10
   22.5 1.462 Triangular 6 10
   22 1 Triangular 6 10
   21 0.423 Triangular 6 10
  At age 75 years
   23.5 2.186 Triangular 6 10
   23 1.465 Triangular 6 10
   22.5 0.93 Triangular 6 10
   22 0.628 Triangular 6 10
   21 0.279 Triangular 6 10
Bone strength
 Mean bone strength at start (10) (N) (7240 – 60.7 3 age) Normal 6 600
 Bone strength loss per year without therapy (10) (%)‡
  Age 45 years 1.3 Triangular 6 10
  Age 55 years 1.5 Triangular 6 10
  Age 65 years 1.75 Triangular 6 10
  Age 75 years 2.2 Triangular 6 10
  Age 85 years 2.8 Triangular 6 10
 Bone strength gain per year under therapy (40) (%) 4 Gamma 6 0.375
 Relative risk for fracture based on bone strength  
(bone strength factor)‡§
  100 2 Triangular 6 10
  1000 1.6 Triangular 6 10
  2000 1.4 Triangular 6 10
  3000 1.2 Triangular 6 10
  3800 1 Triangular 6 10
  5000 0.75 Triangular 6 10
  8000 0.6 Triangular 6 10
Note.—Unless otherwise indicated, base case data are means and PSA data are the standard deviations.
* Data in parentheses are reference numbers.
† Standard deviation is age dependent.
‡ Base case data are means, and the PSA data are the standard deviation as percentage of the mean.
§ Indicates an assumption.
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these 1000 runs, the model was used 
to draw random data points for each 
variable according to the distributions 
provided in Tables 1 and 2 to address 
overall uncertainty of the model.
Results
Main Analysis
Model validation, as shown in Table 3, al-
lowed us to proceed with the analyses. 
The most cost-effective screening strat-
egy was combined DXA/quantitative CT 
with screening initiation at age 55 and 
a quantitative CT screening interval of 
5 years (Tables 4, 5; Fig 2). The total 
number of fractures with that strategy 
was substantially lower compared with 
that with DXA and that with no screening 
(Table 5). With no screening at age 55, 
18.7% of individuals in our cohort sus-
tained a hip fracture during the remain-
der of their life. DXA screening starting 
at age 55 years reduced that percentage 
to 15.8%, while the most cost-effective 
strategy (DXA/quantitative CT at age 
55 years, with a quantitative CT interval 
of 5 years) reduced the lifetime risk to 
12.8%. The corresponding percentages 
of individuals starting screening at age 55 
effectiveness from 0% (undiscounted) 
to 5% (46). We performed threshold 
analyses for major parameters to test 
the potential effect on our model re-
sults. The sensitivity analysis was per-
formed by varying the following param-
eters for a population in which screening 
was initiated at age 55 years, because 
this was the preferred age to start any 
screening: adherence rate, 40%–100%; 
overall fracture rate, 50%–200%; costs 
for DXA, $1–$50; for quantitative CT, 
$100–$1000; and for hip fracture treat-
ment, $10 000–$50 000; utility modifier 
for hip fractures, 0.6–0.9 and for verte-
bral fractures, 0.6–0.9. We calculated the 
net monetary benefits for each strategy 
for willingness-to-pay values of $50 000 
and $100 000. Net monetary benefit was 
calculated by converting QALYs into U.S. 
dollars and then subtracting the costs for 
each strategy. This resulted in the net 
monetary benefit for that specific strat-
egy. The threshold for each parameter 
that resulted in a change in the preferred 
strategy based on net monetary benefits 
was calculated.
PSA Protocol
In PSA, we ran the model 1000 times 
with 100 000 individuals. In each of 
strategy with currently used scenarios 
(no screening and DXA screening). In 
our base case scenario we used 3% 
annual discounting of costs and ef-
fectiveness as suggested by the U.S. 
Panel on Cost-Effectiveness in Health 
and Medicine (46). Strategies with 
costs of $50 000 per QALY were con-
sidered very cost-effective and those of 
$50 000–$100 000 per QALY were con-
sidered cost-effective.
Sensitivity Analyses
We performed deterministic and PSA to 
address the effects of parameter uncer-
tainty on model results. In two separate 
analyses, we increased and decreased 
the overall fracture risk for all fracture 
types by a factor of two (worst and best 
case scenario). In a third analysis, we 
removed the bone strength factor, ne-
glecting the effect of bone strength on 
fracture risk. We used one-way sensi-
tivity analyses to assess different levels 
of medication adherence (40%, 70%, 
100%) and linearly increasing quantita-
tive CT costs (including postprocessing) 
of $215, $340 (hip MR imaging, current 
procedural terminology code 73721), 
$460, $580, and $700. We also var-
ied the annual discounting of costs and 
Figure 2
Figure 2: Graph shows costs (in U.S. dollars) and effectiveness (QALY) of each strategy for main analysis. All strategies above the connect-
ing lines were more expensive and/or less effective and were therefore excluded and not incorporated in Table 4. DXA/quantitative CT (QCT) 
age 60–quantitative CT interval 10 years square is obscured by the DXA/quantitative CT age 60–quantitative CT interval 5 years because the 
squares are in the same position on the graph.
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$53 400 per QALY) (Table 6). The un-
discounted results are also shown in 
Table 6.
The cost-effectiveness of the tested 
strategies was most sensitive to treat-
ment adherence (at a willingness-to-pay 
of $50 000 and $100 000) and the cost 
for quantitative CT (only at willingness-
to-pay of $50 000). Specifically, the 
preferred rescreening interval changed 
from 3 years to 10 years when the treat-
ment adherence rate was increased to 
higher than 74.3% on the basis of net 
monetary benefits. Also, at a cost of 
more than $900, the quantitative CT 
bone strength test rescreening interval 
of 10 years was preferred over a 3-year 
interval. The model results were not 
sensitive to overall fracture rate, DXA 
costs, hip fracture costs, or utilities for 
hip and vertebral fractures (Appendix 
E1 [online]).
was the most cost-effective strategy 
($12 800 per QALY, data not shown). 
With adherence of 100%, DXA/quanti-
tative CT at age 55 years with a 5-year 
interval was very cost-effective ($2600 
per QALY) and DXA/quantitative CT 
at age 55 with a 3-year interval was 
cost-effective ($75 900 per QALY [data 
not shown]).
Increasing quantitative CT costs had 
little effect on the results. With quan-
titative CT costs of $215–$700, DXA/
quantitative CT at age 55 years with a 
5-year interval was the most cost-effec-
tive strategy (only data for quantitative 
CT costs of $700 are shown in Table 
6). With 5% annual discounting, DXA/
quantitative CT at age 55 years with a 
5-year interval was very cost-effective 
(ICER, $4800 per QALY) and DXA/
quantitative CT at age 55 years with a 
3-year interval was cost-effective (ICER, 
years for vertebral fractures were 11.1% 
for no screening, 9% for DXA screening, 
and 7.5% for DXA/quantitative CT with 
a 5-year interval, for other fractures, 
30.8%, 27.3%, and 22.6%, respectively; 
and for wrist fractures, 17.8%, 16.4%, 
and 14%, respectively.
Sensitivity Analyses
The DXA/quantitative CT strategies at 
age 55 years remained the most cost-ef-
fective screening strategies for assess-
ment of those with increased or de-
creased overall fracture risks (Table 6). 
In the analysis for decreased fracture 
risk, the best interval for quantitative 
CT rescreening after DXA/quantitative 
CT at age 55 was every 5 years. With 
increased fracture risk, the 3-year in-
terval was very cost-effective, with 
a cost of $440 per QALY, while the 
5-year interval was not cost-effective, 
with a cost of $205 400 per QALY. 
When the bone strength factor (the ef-
fect of bone strength on fracture risk) 
was not considered, DXA/quantitative 
CT at age 55 years with a 5-year in-
terval remained the most cost-effective 
strategy (Table 6).
With treatment adherence of 70%, 
DXA/quantitative CT at age 55 years 
with a 3-year interval was the most 
cost-effective strategy (Table 6). With 
adherence lower than that in the base 
case (40% adherence), DXA/quantita-
tive CT at age 55 with a 5-year interval 
Table 4
Results of Main Analysis (Base Case) 
Strategy Age (y) Interval (y)* Cost QALY ICER
DXA/quantitative CT 65 5 17 570 10.80 NA
DXA/quantitative CT 65 10 17 580 10.83 200
DXA 55 NA 18 860 14.08 400
DXA/quantitative CT 55 5 19 490 14.40 2000
Note.—Screening strategies not shown were excluded because of absolute or weak dominance. The included strategies were 
cost-saving compared with strategies not shown. NA = not applicable.
* Interval indicates the time between quantitative CT examinations.
† ICER = Cost in U.S. dollars per QALY gained.
Table 5
Results of Base Case Analysis Fractures and Mortality
Variable
DXA/Quantitative CT at  
Age 55, Interval 5 years DXA at Age 55
No Screening  
at Age 55
Total no. of fractures 657 000 (100) 793 700 (100) 935 600 (100)
 Hip fractures 131 800 (20) 163 000 (21) 196 200 (21)
 Vertebral fractures 80 900 (12) 96 500 (12) 121 500 (13)
 Other fractures 289 000 (44) 352 700 (44) 417 400 (45)
 Wrist fractures 155 300 (24) 181 500 (23) 200 500 (21)
Mortality, mean age at death (y)* 84.8 6 8.5 84.6 6 8.4 84.6 6 8.4 
Note.—Data are number of fractures, with percentage in parentheses. Fractures for the most cost-effective screening strategy 
(DXA and quantitative CT at age 55, with a CT interval of 5 years) compared with current guidelines (DXA and FRAX) and no 
screening for the same starting age. Mortality was lower for the DXA/quantitative CT screening strategy due to a reduction in hip 
fractures and their associated risks of death.
* Data are means 6 standard deviation.
Table 3
Model Validation
Age 65, No Screening
Model 
Precast Literature
Life expectancy (y) 19.6 20.5 (16)
Hip fractures
 Lifetime 19 18–20 (47,48)
 By age 90 years 16.3 16.3 (49)
Wrist fractures by  
age 85 years
15.6 14.5 (50)*
Vertebral fractures  
by age 90 years
10.2 12.3 (50)†
Note.—Unless otherwise indicated, data are per- 
centages, with the references in parentheses.
* By age 85 for women between 60–69 years.
† After 20 years for women between 60–69 years.
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of 1000). At the $100 000 per QALY 
threshold, results were similar: The 
best strategy was DXA/quantitative CT 
at age 55 with a 5-year interval in 92% 
(920 of 1000) of iterations, followed 
by DXA (4.4%, 44 of 1000) and DXA/
quantitative CT at age 55 with a 3-year 
interval (3.6%, 36 of 1000).
Discussion
Our model showed that the addition of 
bone strength testing to currently ex-
isting DXA screening recommendations 
for postmenopausal women would be 
cost-saving compared with no screen-
ing (ie, total cost of screening, prophy-
laxis, and treatment would be lower 
compared with no screening) and very 
cost-effective compared with DXA and 
use of the FRAX tool screening. The 
3-year and 5-year quantitative CT re-
screening intervals were cost-effective 
for the combined DXA/quantitative 
CT strategies, depending on the differ-
ent parameters used in our sensitivity 
analysis. In general, screening initiation 
at age 55 years was more cost-effec-
tive compared with screening initiation 
at a later age. The overall most favor-
able screening strategy was combined 
DXA/quantitative CT at age 55 years 
with a 5-year screening interval. With 
this strategy, the number of fragility 
fractures and the associated morbidity 
and mortality were substantially re-
duced. Therefore, bone strength testing 
could provide a cost-effective tool to 
add to current osteoporosis screening 
programs in postmenopausal women.
Osteoporosis is characterized by 
low bone mass and microarchitectural 
deterioration of bone tissue, which to-
gether cause reduced bone strength 
(1). DXA assessment of areal BMD 
does not completely capture bone 
strength in mechanical testing studies. 
Therefore, bone strength testing could 
provide important missing information 
to improve clinicians’ ability to assess 
fracture risk (51). We acknowledge 
that bone strength testing is not widely 
available and is limited mostly to large 
medical centers or research groups. 
However, U.S. Food and Drug Adminis-
tration–approved bone strength testing 
was the most cost-effective strategy, 
at the $50 000 per QALY threshold in 
90.4% (904 of 1000) of iterations, fol-
lowed by DXA at age 55 (5.4%, 54 of 
1000) and DXA/quantitative CT at age 
55 with a 3-year interval (4.2%, 42 
PSA Results
DXA/quantitative CT at age 55 with a 
5-year interval was the most cost-effec-
tive strategy (as in our main analysis) 
(Table 6). DXA/quantitative CT at age 
55 with a screening interval of 5 years 
Table 6
Results of Sensitivity Analyses
Strategy Start Age (y) Interval (y)* Cost ($) QALYs ICER†
50% fracture rate
 DXA 65 NA 10 770 10.88 NA
 DXA 55 NA 11 290 14.31 150
 DXA/quantitative CT 55 10 12 390 14.53 5100
 DXA/quantitative CT 55 5 13 060 14.58 11 500
200% fracture rate
 DXA/quantitative CT 65 3 29 050 10.59 NA
 DXA/quantitative CT 55 3 30 600 14.08 440
 DXA/quantitative CT 55 5 30 960 14.08 205 400
Bone strength factor = 1
 DXA 65 NA 14 070 10.79 NA
 DXA 55 NA 14 350 14.22 80
 DXA/quantitative CT 55 5 16 320 14.51 6800
70% adherence
 DXA/quantitative CT 65 5 17 150 10.82 NA
 DXA 60 NA 17 830 12.46 420
 DXA 55 NA 18 580 14.12 450
 DXA/quantitative CT 55 10 19 040 14.37 1900
 DXA/quantitative CT 55 5 19 300 14.42 5500
 DXA/quantitative CT 55 3 19 520 14.43 20 400
Quantitative CT costs $700
 DXA 65 NA 18 260 10.72 NA
 DXA 60 NA 18 460 12.42 120
 DXA 55 NA 18 720 14.09 150
 DXA/quantitative CT 55 10 19 930 14.33 5000
 DXA/quantitative CT 55 5 20 360 14.40 5800
0% discounting (undiscounted)
 DXA/quantitative CT 65 5 27 500 14.68 NA
 DXA/quantitative CT 60 5 30 490 17.78 960
 DXA/quantitative CT 55 3 34 740 21.65 1100
 DXA/quantitative CT 55 5 34 790 21.68 1950
5% discounting
 DXA 55 NA 13 290 11.31 NA
 DXA/quantitative CT 55 10 13 880 11.45 4400
 DXA/quantitative CT 55 5 14 070 11.49 4800
 DXA/quantitative CT 55 3 14 350 11.49 53 400
PSA
 DXA/quantitative CT 65 5 21 980 10.7 NA
 DXA/quantitative CT 55 5 23 980 13.31 560
Note.—Screening strategies not shown in this Table were ruled out because of absolute or weak dominance. Bone strength 
factor = 1 means that the effect of bone strength on fracture risk was neglected. Results for PSA are the average of all 1000 
simulations. NA = not applicable.
* Interval indicates the time between quantitative CT examinations. DXA intervals were T score dependent.
† ICER = cost in U.S. dollars per QALY gained.
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evidence in the literature regarding bone 
strength and fracture prediction is small 
compared with that for DXA. Therefore, 
we had to calculate fracture risk of other 
anatomic locations (ie, spine, wrist, 
others) on the basis of bone strength 
values measured at the hip. In a simi-
lar way, we only used hip T scores to 
assess fracture risk at other anatomic 
locations. However, hip T scores do have 
predictive value for fractures at other 
locations (58). We did not incorporate 
adverse effects from alendronate treat-
ment into our model. In a randomized, 
double-blind trial (59), alendronate 
did not result in a substantially higher 
number of adverse effects in the upper 
gastrointestinal tract when compared 
with placebo. Our model inputs consist-
ed mostly of data from American white 
women and the model is specific to U.S. 
health care. Finally, we did not include 
the potential effects of ionizing radia-
tion on the model. However, the risks 
of radiation-induced cancers have been 
shown to be minimal in the age range 
for our study (60). The lifetime risk of 
death from radiation-induced cancer 
for a single abdominal CT examination 
(radiation of approximately 10 mSv) at 
age 55 years or older is estimated to be 
less than 0.01% (61). However, quanti-
tative CT of the hip has a lower radi-
ation dose (approximately 2.5–3 mSv) 
(62), and therefore, is presumed to have 
a lower risk of death from radiation-in-
duced cancer. As stated previously, bone 
strength also can be computed with MR 
imaging as a radiation-free alternative 
to quantitative CT. In conclusion, the 
combined assessment of bone strength 
and BMD for osteoporosis in postmeno-
pausal women has the potential to be a 
cost-effective screening strategy and to 
prevent a substantial number of fragility 
fractures.
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This should be addressed in future iter-
ations of the model.
We used quantitative CT in our 
model, because much more literature 
was available on bone strength derived 
with quantitative CT than that derived 
with MR imaging (55). However, bone 
strength also can be assessed with MR 
imaging without the use of ionizing 
radiation (9). Although MR imaging 
of the hip is more expensive than CT 
of the hip, we showed that increasing 
costs for bone strength testing had only 
a minor effect on cost-effectiveness. 
Therefore, we consider bone strength 
testing with MR imaging as a poten-
tial alternative to testing with quanti-
tative CT. Although MR imaging does 
not provide BMD information, that in-
formation is already provided at DXA. 
Of note, textural analysis of the femur 
on pelvic radiographs is another option 
for assessment of fracture risk and is 
better for prediction of fragility fracture 
compared with DXA (56). In a recent 
cadaver study (57), investigators com-
pared finite element–based quantitative 
CT (as used in our model) with DXA, 
radiography, and CT-based bone mea-
surement for femur fracture prediction. 
That study showed that quantitative CT 
was the best method for prediction of 
failure load (57).
Our model had limitations. We as-
signed start values for BMD and bone 
strength to each individual separately. 
The proportion of our cohort with 
low BMD and low bone strength was 
constant due to the normal distribution 
of both parameters. However, because 
the model assigned both values inde-
pendently in each simulation, the over-
lap between these two proportions 
could change. Therefore, the number 
of individuals identified for treatment 
may have changed between different 
analyses. However, this uncertainty was 
addressed in the PSA. We modeled per-
fect test properties for the DXA and 
quantitative CT tests, meaning that both 
tests exactly measured the simulated 
BMD and bone strength, respectively. 
Another limitation was the assump-
tion of the bone strength factor. How-
ever, this assumption was tested in the 
sensitivity analyses. Also, the body of 
is available (VirtuOst; O.N. Diagnos-
tics, Berkeley, Calif). In our study, we 
did not vary the cutoff values for treat-
ment initiation (ie, T scores, bone 
strength, FRAX score) in the sensitivity 
analyses. However, the cutoff value for 
low femoral bone strength (, 3000 N) 
was defined in the study by Keaveny et 
al (10) for women and men. The cutoff 
was derived from results of a prospec-
tive study in elderly men in which all 
patients with new hip fractures had a 
femoral bone strength of less than 2900 
N (52).
Authors of previous studies have 
used similar state-transition model 
structures, assessing multiple differ-
ent screening strategies at different 
ages (53). Although they did not find 
one strategy that clearly outperformed 
others, they also found that screening 
initiation at age 55 years was cost-ef-
fective. The National Osteoporosis 
Foundation, the American Congress of 
Obstetricians and Gynecologists, and 
the U.S. Preventive Services Task Force 
recommend osteoporosis screening for 
women age 65 years and older and in 
postmenopausal women with increased 
risk (eg, those with clinical risk factors) 
(54).
In other cost-effectiveness studies, 
DXA screening strategies consisted of 
fixed rescreening intervals (49). Au-
thors of other studies looked at the 
time interval in which 10% of postmen-
opausal women with normal to mild, 
moderate, or advanced osteopenia 
developed osteoporosis by conducting 
competing risk analyses in 4957 post-
menopausal women with no osteoporo-
sis at baseline and follow-up of up to 
15 years (43). We based the flexible 
DXA screening intervals on those in 
that study, which was a strength of our 
model. However, we did not investigate 
more aggressive DXA screening inter-
vals and treatment strategies. Further 
strengths of our model were the inclu-
sion of the FRAX tool, the patient-level 
simulation of bone strength, and the 
addition of a bone strength test. The re-
screening interval of our bone strength 
test was fixed. Personalized screening 
intervals based on bone strength may 
result in even higher cost-effectiveness. 
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